SPC
NBIX icon

Sigma Planning Corp’s Neurocrine Biosciences NBIX Stock Holding History

Sigma Planning Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000
Closed -$230K – 1226
2024
Q3 		$230K Buy
+2,000
New +$274K 0.01% 1074
2024
Q2 		– Sell
-10,100
Closed -$1.39M – 1237
2024
Q1 		$1.39M Buy
+10,100
New +$1.38M 0.04% 403
2020
Q3 		– Sell
-3,795
Closed -$463K – 1131
2020
Q2 		$463K Buy
+3,795
New +$419K 0.02% 622
2018
Q4 		– Sell
-2,370
Closed -$291K – 929
2018
Q3 		$291K Hold
2,370
– – 0.02% 708
2018
Q2 		$233K Sell
2,370
-1,020
-30% -$91.3K 0.02% 764
2018
Q1 		$281K Buy
3,390
+290
+9% +$24.5K 0.02% 633
2017
Q4 		$241K Buy
+3,100
New +$211K 0.02% 695

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sigma Planning Corp's NBIX Position: Q4 2024 in Review

Sigma Planning Corp sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 2,000 shares — an estimated $230K sold.

Sigma Planning Corp first reported a position in NBIX in Q4 2017 and held it in 7 quarters. The position peaked at $1.39M in Q1 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Sigma Planning Corp reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Sigma Planning Corp sold 2,000 Neurocrine Biosciences shares in Q4 2024, an estimated $230K.
  • Sigma Planning Corp first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 7 quarters.
  • Sigma Planning Corp's Neurocrine Biosciences position peaked at $1.39M in Q1 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Sigma Planning Corp's 13F filing for Q4 2024, filed 3 Feb 2025.